Skip to content
    Real-World Studies

    Lymph Node Retrieval Extent and Outcomes in Older Adults Undergoing Gastrectomy

    Kim et alAnnals of Surgical Oncology

    Lymph Node Retrieval Extent and Outcomes in Older Adults Undergoing Gastrectomy
    In curative-intent surgery for gastric adenocarcinoma, the optimal extent of lymphadenectomy in older adults has remained uncertain due to potential trade-offs between postoperative morbidity and overall survival benefits.
    Using the National Cancer Database, investigators evaluated 47,342 patients with stage I–III gastric adenocarcinoma who underwent gastrectomy between 2010 and 2022, including 11,235 patients aged 75 years or older. Patients were stratified by age (< 55, 55–64, 65–74, and ≥ 75 years) and by the number of lymph nodes examined (< 16, 16–24, 25–34, and ≥ 35). Multivariable Cox regression was used to evaluate overall survival, and multivariable logistic regression evaluated modified textbook short-term outcomes, encompassing 30-day mortality, readmission, and hospital length of stay exceeding the 75th percentile. Sensitivity analyses were conducted in subgroups aged ≥ 80 and ≥ 85 years.
    Retrieval of ≥ 35 lymph nodes compared to < 16 was associated with improved overall survival in every age category: < 55 years (hazard ratio [HR] 0.72; 95% confidence interval [CI] 0.59–0.87), 55–64 years (HR 0.66; 95% CI 0.57–0.77), 65–74 years (HR 0.67; 95% CI 0.58–0.76), and ≥ 75 years (HR 0.74; 95% CI 0.61–0.91). This survival association persisted among patients receiving preoperative chemotherapy as well as those aged 80 years and older. Furthermore, higher nodal retrieval was not associated with increased odds of adverse modified textbook short-term outcomes across any cohort, suggesting that age alone should not guide the decision to restrict lymphadenectomy during resectable gastric cancer surgery.

    Key Takeaways

    • Examination of ≥ 35 lymph nodes compared with < 16 nodes was associated with improved overall survival across all age groups, including patients aged ≥ 75 years (HR 0.74, 95% CI 0.61–0.91), 65–74 years (HR 0.67, 95% CI 0.58–0.76), 55–64 years (HR 0.66, 95% CI 0.57–0.77), and < 55 years (HR 0.72, 95% CI 0.59–0.87), with persistence in patients aged ≥ 80 years and those receiving preoperative chemotherapy.
    • Greater nodal yield was not associated with higher odds of adverse modified textbook short-term outcomes—defined by 30-day mortality, readmission, and length of stay > 75th percentile—in any evaluated age group.
    Read the original sourceAnnals of Surgical Oncology